Antitumor activity of benzamide riboside in vitro and in vivo

Curr Med Chem. 2002 Apr;9(7):773-9. doi: 10.2174/0929867024606894.

Abstract

Benzamide riboside (BR), a recent synthetic nucleoside analogue, is a new compound demonstrating potent cytotoxic activity in malignant cell lines in vitro and in vivo in L1210 leukemia. It exhibits at least two different mechanisms of action. These are, first, the inhibition of inosine 5'-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205), a rate-limiting enzyme for GTP and dGTP synthesis that plays a major role in DNA synthesis, cell proliferation and regulation; and second, the induction of apoptosis. Some aspects of BR activity in malignant cells in vitro and in vivo are reviewed as well as some of the mechanisms behind BR's anti-neoplastic effect.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Cell Division / drug effects
  • DNA Replication / drug effects
  • Female
  • Humans
  • IMP Dehydrogenase / antagonists & inhibitors*
  • In Vitro Techniques
  • Leukemia L1210 / drug therapy
  • Leukemia L1210 / enzymology
  • Nucleosides / pharmacology*
  • Ovarian Neoplasms / drug therapy
  • Staurosporine / administration & dosage
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Nucleosides
  • 3-(1-deoxyribofuranosyl)benzamide
  • IMP Dehydrogenase
  • Staurosporine